New Jersey-based GlucoTrack has completed the first preclinical study with its implantable continuous glucose monitor (CBGM) and is preparing for first-in-human studies, with trial initiation expected this year.

The implantable CBGM is placed subcutaneously and connected to a lead placed directly into a blood vessel. This allows for zero lag time when taking continuous blood glucose measurements. The company aims to develop the CGBM device with a long sensor life, which does not require additional wearable components and has a once-only calibration event.

The preclinical study assessed the implantation technique and device safety. The implant approach was based on commonly used cardiovascular implantable devices and the implantation procedure took approximately 20 minutes.

GlucoTrack’s CEO Paul Goode said: “The intravascular approach creates a system that is truly differentiated in the diabetes market. By measuring glucose in the blood, our system operates in a way that is comparable to what people expect with conventional fingerstick blood glucose monitoring. And we accomplish this on a continuous basis with long-term use, improved simplicity, and increased discretion.”

The company has also initiated long-term preclinical testing on the implantable CBGM. The study aims to assess sensor accuracy and longevity with a refined prototype and a larger sample size.

A popular method of managing blood sugar levels is by continuous glucose monitoring devices. The glucose monitoring market is expected to grow from being worth approximately $5.15bn in 2023 to $7.7bn in 2030, as per the GlobalData market model.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

GlobalData is the parent company of Clinical Trials Arena.

Multiple companies have developed different approaches to monitor glucose levels, with a focus on non-invasive measures. Know Labs has developed a non-invasive glucose monitor, which measures blood sugar levels by sending radio waves through the skin to capture molecular signatures. In August 2023, Nemaura Medical received approval from the Saudi Food and Drug Authority for its non-invasive wearable glucose sensor sugarBEAT.

Apart from glucose monitoring, new approaches to diabetes control and management are also in development. In October 2023, Sigrid Therapeutics started a clinical trial for the diabetes and obesity control device SiPore21. The device acts similarly to a “molecular sieve” to reduce food breakdown and absorption.